Meta-analysis of real-world studies associates COVID-19 vaccination with improved survival in cancer patients on ICIs
Cancer Patients Live Longer After COVID Shots
This meta-analysis of real-world studies evaluated 4,929 cancer patients receiving immune checkpoint inhibitors to assess COVID-19 vaccinati…
It started with a question doctors couldn’t answer: *Should patients on powerful cancer drugs get the COVID vaccine?* Some worried the immun…
Review of multi-omics technologies supporting immune checkpoint inhibitor use in cancer patients
New Data Helps Doctors Pick Better Cancer Treatments
This review examines the application of multi-omics technologies within cancer patients treated with immune checkpoint inhibitors.
Using many types of medical data helps doctors choose the right cancer drugs for each person.
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Mini-review discusses combination regimens built on immune checkpoint inhibitors and their associated immune-related adverse events
How Doctors Are Learning to Stop Cancer Therapy From Backfiring
This mini-review examines combination regimens built on immune checkpoint inhibitors (ICIs).
This research gives doctors a roadmap to predict and prevent dangerous side effects from powerful cancer treatments.
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
Does your lung cancer's genetic makeup change how well immune therapy works?
This narrative review explores how targetable driver gene alterations in non-small cell lung cancer (NSCLC) influence the tumor immune micro…
Lung cancer's genetic drivers actively reshape the tumor's immune environment, causing immunotherapy to work differently depending on a pati…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients
A review suggests innate immunity plays a key role in cancer drug side effects
This systematic review evaluated immune checkpoint inhibitors (ICIs) in patients with cancer, focusing on immune-related adverse events (irA…
Cancer drugs that help fight tumors can also cause serious inflammation, and new research shows the body's first line of defense plays a key…
Combined neutrophil-to-lymphocyte ratio predicts progression-free survival in metastatic cervical cancer patients treated with immune checkpoint inhibitors
A Simple Blood Test May Predict Cervical Cancer Treatment Success
This retrospective cohort analysis evaluated 148 individuals with metastatic or recurrent cervical cancer treated with immune checkpoint inh…
A simple blood test ratio may predict who responds best to immunotherapy for advanced cervical cancer, helping doctors tailor treatment with…
Immune Checkpoint Inhibitors Improve Survival and Response Rates in Patients with Hepatocellular Carcinoma Compared to Standard Therapy
New Drug Gives Liver Cancer Patients More Time
This systematic review and meta-analysis evaluated immune checkpoint inhibitors (ICIs) versus standard therapy or placebo in patients with h…
A new drug helps the immune system fight liver cancer, giving patients more time and better survival rates compared to standard treatments.
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
The Liver Cancer Treatment That Works Better Depending on Your History
This systematic review and meta-analysis of seventeen studies evaluated immune checkpoint inhibitor (ICI)-based regimens versus tyrosine kin…
Immunotherapy beats older drugs for advanced liver cancer, especially when hepatitis B caused the disease, but benefits depend on your liver…